<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pharmacol</journal-id><journal-title>BMC Pharmacology</journal-title><issn pub-type="epub">1471-2210</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15617579</article-id><article-id pub-id-type="pmc">PMC545955</article-id><article-id pub-id-type="publisher-id">1471-2210-4-32</article-id><article-id pub-id-type="doi">10.1186/1471-2210-4-32</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models <italic>in vivo</italic></article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Lu</surname><given-names>Da-Yong</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>ludayong@sh163.net</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Xu</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bxu@mail.shcnc.ac.cn</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Ding</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>jding@mail.shcnc.ac.cn</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Anticancer Pharmacology, Shanghai Institute of Materia Medica, Shanghai Institutes of Biology Sciences, Chinese Academy of Sciences, Shanghai 201203, PR China</aff><aff id="I2"><label>2</label>School of Life Sciences, Shanghai University, Shanghai 200436, PR China</aff><aff id="I3"><label>3</label>Graduate School of Chinese Academy of Sciences, PR China</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>24</day><month>12</month><year>2004</year></pub-date><volume>4</volume><fpage>32</fpage><lpage>32</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2210/4/32"/><history><date date-type="received"><day>3</day><month>10</month><year>2004</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Lu et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Lu et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Lu
               Da-Yong
               
               
               
               ludayong@sh163.net
            </dc:author><dc:title>
            Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo
         </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>BMC Pharmacology 4(1): 32-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2210(2004)4:1&#x0003c;32&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2210</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Probimane (Pro), an anti-cancer agent originating in China, was derived from razoxane (ICRF-159, Raz), a drug created in Britain, specifically targeting at cancer metastasis and as a cardioprotectant of anthrocyclines. Pro and Raz are bisdioxopiperazine compounds. In this work, we evaluated the anti-tumor and anti-metastatic effects of Pro and Raz <italic>in vivo </italic>against two lung tumor models, one of murine origin (Lewis lung carcinoma, LLC) and one of human origin (LAX-83).</p></sec><sec><title>Results</title><p>After determining the lethal dosage of Pro and Raz, we assessed and compared the inhibitory effects of Pro and Raz against primary tumor growth and metastatic occurrences of LLC at the dosage of LD<sub>5</sub>. Pro and Raz were active against primary tumor growth and significantly inhibited pulmonary metastasis of LLC at same dose-ranges (inhibitory rates &#x0003e; 90 %). Both Raz and Pro were effective in 1, 5, and 9 day administration schedules. Three different schedules of Raz and Pro were effective against the primary tumor growth of LLC (35&#x02013;50 %). The synergistic anticancer effect of Raz with bleomycin (Ble) (from 41.3 % to 73.3 %) was more obvious than those with daunorubicin (Dau) (from 33.1 % to 56.3 %) in the LLC tumor model. Pro was also seen to have synergistic anti-cancer effects with Ble in the LLC model. Both Raz and Pro inhibited the growth of LAX 83 in a statistically significant manner.</p></sec><sec><title>Conclusions</title><p>These data suggest that both Raz and Pro may have anti-tumor potentiality and Raz and Pro have combinative effects with Ble or Dau. The potential targets of bisdioxopiperazines may include lung cancers, especially on tumor metastasis. The anti-cancer effects of Raz and Pro can be increased with the help of other anticancer drugs.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Razoxane (ICRF-159) (<italic>Raz</italic>), first developed in UK, was the earliest agent against spontaneous metastasis for the murine model (Lewis lung carcinoma) in 1969 [<xref ref-type="bibr" rid="B1">1</xref>]. A large volume of papers and projects have been published in the utilities and mechanisms of <italic>Raz </italic>for anticancer actions, like assisting radiotherapy, [<xref ref-type="bibr" rid="B2">2</xref>] overcoming multi-drug resistance (MDR) of daunorubicin and doxorubicin [<xref ref-type="bibr" rid="B3">3</xref>], inhibiting topoisomerase II [<xref ref-type="bibr" rid="B4">4</xref>] and so on. More importantly, <italic>Raz</italic>, as a cardioprotectant of anthrocyclines, has been licensed in 28 countries in 4 continents. Since morpholine groups in some structures were reported to be responsible for cytotoxic or modulative actions on tumors, an anticancer agent, probimane [1,2-bis (N<sup>4</sup>-morpholine-3, 5-dioxopeprazine-1-yl) propane; AT-2153, Pro] was synthesized by introducing two morpholine groups into <italic>Raz </italic>in China.[<xref ref-type="bibr" rid="B5">5</xref>]. <italic>Raz </italic>and <italic>Pro </italic>belong to <italic>bisdiopiperazines</italic>. Like <italic>Raz</italic>, <italic>Pro </italic>also exhibits anti-tumor activity both <italic>in vivo </italic>and <italic>in vitro </italic>against experimental tumor models in a small scale investigation [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>] and limited clinical data showed that <italic>Pro </italic>could inhibit human malignant lymphoma even for those resistant to other anticancer drugs [<xref ref-type="bibr" rid="B8">8</xref>]. Pro exhibits the same pharmacological effects as <italic>Raz</italic>, like detoxication of <italic>Adriamycin </italic>(<italic>ADR</italic>) induced cardiotoxicities, and synergism with <italic>ADR </italic>against tumors [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. We have found some novel biological effects of <italic>Pro</italic>, like inhibiting the activity of calmodulin (<italic>CaM</italic>), a cell-signal regulator, which can explain anticancer actions and the combined cytotoxic effect of <italic>Pro </italic>and <italic>ADR </italic>[<xref ref-type="bibr" rid="B11">11</xref>]. Pro was also shown to inhibit lipoperoxidation (<italic>LPO</italic>) of erythrocytes [<xref ref-type="bibr" rid="B12">12</xref>], influence tumor sialic acid synthesis [<xref ref-type="bibr" rid="B13">13</xref>] and inhibit the binding of fibrinogen to leukemia cells [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Lung cancer is the No 1 killer among all categories of cancers in urban areas in China and many Western countries. The high mortality rate of lung cancer can easily be caused by inducing multi-drug resistance (<italic>MDR</italic>) and by high metastatic occurrence in clinics [<xref ref-type="bibr" rid="B15">15</xref>]. Since we assume that <italic>Pro</italic>, like <italic>Raz </italic>may possess useful therapeutic potentialities, we evaluated <italic>in vivo </italic>the chemotherapeutical parameters of <italic>Pro </italic>and <italic>Raz </italic>for lung cancer of both murine and human origins.</p></sec><sec><title>Results</title><sec><title>Lethal toxicity of Pro and Raz in mice</title><p>The lethal dosage of <italic>Pro </italic>and <italic>Raz </italic>is tabulated in Table <xref ref-type="table" rid="T1">1</xref>. Since the toxicity of <italic>Pro </italic>and <italic>Raz </italic>seemed to lack sex specificity in mice, we were able to combine their numbers for LD<sub>50 </sub>and LD<sub>5 </sub>calculations. We used the approximate dosage of LD<sub>5 </sub>of Pro (60 mg/kg ip &#x000d7; 7) and Raz (20 mg/kg ip &#x000d7; 7) as equitoxic dosages for further treatment studies.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>The subacute toxicity of Pro and Raz in mice: Mouse survival was observed for 1 month. The numbers of mice in each group were 20 for each of the 5 dosages of a single agent.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Drugs</td><td align="center">Protocols</td><td align="center">LD<sub>5 </sub>mg/kg</td><td align="center">LD<sub>50 </sub>mg/kg</td></tr></thead><tbody><tr><td align="center">Probimane</td><td align="center">ip &#x000d7; 10</td><td align="center">66</td><td align="center">121</td></tr><tr><td align="center">Razoxane</td><td align="center">ip &#x000d7; 10</td><td align="center">23</td><td align="center">53</td></tr></tbody></table></table-wrap></sec><sec><title>Antitumor and antimetastatic effects of Pro and Raz on LLC</title><p>Antitumor and antimetastatic effects of <italic>Pro </italic>and <italic>Raz </italic>on <italic>LLC </italic>are tabulated in Table <xref ref-type="table" rid="T2">2</xref> and Table <xref ref-type="table" rid="T3">3</xref>. <italic>Pro </italic>and <italic>Raz </italic>at equitoxic dosages (LD<sub>5</sub>) showed a noticeable anticancer effect on primary tumor growth (inhibitory rates, approximately 30&#x02013;45 %), and significantly inhibited the formation of tumor metastases (inhibitory rates on pulmonary metastasis &#x0003e; 90 %, P &#x0003c; 0.001). Primary tumor growth of <italic>LLC </italic>was inhibited more by <italic>Pro </italic>(48 %) than by <italic>Raz </italic>(40.3%) in a 20 day trial, whereas the inhibition of <italic>Pro </italic>(35.7%) was slightly less than that of <italic>Raz </italic>(40 %) on an 11 day trial. Pro seems to be more persistent than Raz in inhibiting primary tumor growth of <italic>LLC</italic>.</p></sec><sec><title>Antitumor effects of bisdioxopiperazines for different schedules and in combination with other anticancer drugs</title><p>Antitumor effects of <italic>Raz </italic>and <italic>Pro </italic>on <italic>LLC </italic>are included in Table <xref ref-type="table" rid="T4">4</xref>, <xref ref-type="table" rid="T5">5</xref>, <xref ref-type="table" rid="T6">6</xref>. We evaluated 1, 5 and 9 day administration schedules in our study. We found that <italic>Raz </italic>and <italic>Pro </italic>were effective in a statistically significant manner with the 3 injection schedule of the 1, 5 and 9 day administrations on <italic>LLC</italic>. If we administered <italic>Raz </italic>to tumor-bearing mice once on day 1, 5 and 9, there was no difference between treatment and vehicle control. Antitumor effects of <italic>Raz </italic>in combination with <italic>Ble </italic>on <italic>LLC </italic>(73.3 %) were better than those in combination with <italic>Dau </italic>(56.3 %) (Table <xref ref-type="table" rid="T5">5</xref> and Table <xref ref-type="table" rid="T6">6</xref>). <italic>Pro </italic>also showed synergistic effects in combination with <italic>Ble </italic>(Table <xref ref-type="table" rid="T7">7</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>The influence of Pro and Raz on primary tumor of LLC (using Student T-test): Route: ip &#x000d7; 7 daily. Experiment term was 11 days. * P &#x0003c; 0.05 (treatment vs vehicle control). The numbers of mice were 30 for the control group and 20 for each treatment group. 100 % survival was observed in each group.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Compounds</td><td align="center">Dosage mg/kg/d</td><td align="center">Body weight (g)</td><td align="center">Tumor weight (g)</td><td align="center">Tumor inhibition%</td></tr></thead><tbody><tr><td align="center">Control</td><td align="center">--</td><td align="center">23.3/24.4</td><td align="center">2.80 &#x000b1; 0.04</td><td align="center">--</td></tr><tr><td align="center">Razoxane</td><td align="center">20</td><td align="center">23.3/23.4</td><td align="center">1.61 &#x000b1; 0.03*</td><td align="center">40.0</td></tr><tr><td align="center">Probimane</td><td align="center">30</td><td align="center">23.4/21.6</td><td align="center">1.91 &#x000b1; 0.03*</td><td align="center">32.1</td></tr><tr><td align="center">Probimane</td><td align="center">60</td><td align="center">23.3/23.8</td><td align="center">1.80 &#x000b1; 0.03*</td><td align="center">35.7</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>The influence of Pro and Raz on primary and metastatic tumor of LLC: PTI (%) &#x02013; Primary tumor inhibition. MFCPM &#x02013; metastatic foci count per mouse. Route: ip &#x000d7; 7 every 2 days. Experiment term was 20 days, * P &#x0003c; 0.001(treatment vs vehicle control). The numbers of mice were 30 for both control group and each treatment group. 100 % survival was observed in each group.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Compounds</td><td align="center">Dosage mg/kg/d</td><td align="center">Body weigh (g)</td><td align="center">PTI(%)</td><td align="center">MFCPM</td></tr></thead><tbody><tr><td align="center">Control</td><td align="center">---</td><td align="center">22.8/21.4</td><td align="center">--</td><td align="center">30.9 &#x000b1; 7.3</td></tr><tr><td align="center">Razoxane</td><td align="center">20</td><td align="center">22.7/21.5</td><td align="center">40.3</td><td align="center">1.2 &#x000b1; 0.5*</td></tr><tr><td align="center">Probimane</td><td align="center">30</td><td align="center">23.3/22.5</td><td align="center">42.0</td><td align="center">1.5 &#x000b1; 0.5*</td></tr><tr><td align="center">Probimane</td><td align="center">60</td><td align="center">23.3/20.3</td><td align="center">48.0</td><td align="center">1.0 &#x000b1; 0.2*</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Antitumor effects of bisdioxopiperazines of different schedules on Lewis lung carcinoma: *Administration every 3 hours, 16 mice were included in each testing group. **p &#x0003c; 0.05 (treatment vs control), Experimental term was 11 days</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Compounds</td><td align="center">Dosage</td><td align="center">Schedule</td><td align="center">Tumor weight</td><td align="center">Tumor inhibition</td></tr><tr><td></td><td></td><td colspan="1"><hr></hr></td><td></td><td></td></tr><tr><td></td><td align="center">mg/kg</td><td align="center">1, 5, 9 administrations</td><td align="center">(g)</td><td align="center">%</td></tr></thead><tbody><tr><td align="center">Control</td><td align="center">--</td><td align="center">--</td><td align="center">2.36 &#x000b1; 0.05</td><td></td></tr><tr><td align="center">Razoxane</td><td align="center">80</td><td align="center">1 time a day</td><td align="center">2.49 &#x000b1; 0.05</td><td align="center">-5.5</td></tr><tr><td align="center">Razoxane</td><td align="center">40</td><td align="center">1 time a day</td><td align="center">2.32 &#x000b1; 0.07</td><td align="center">1.7</td></tr><tr><td align="center">Razoxane</td><td align="center">20</td><td align="center">1 time a day</td><td align="center">2.80 &#x000b1; 0.06</td><td align="center">-18.6</td></tr><tr><td align="center">Razoxane</td><td align="center">10</td><td align="center">3 times a day*</td><td align="center">1.51 &#x000b1; 0.04**</td><td align="center">36.0</td></tr><tr><td align="center">Probimane</td><td align="center">20</td><td align="center">3 time a day*</td><td align="center">1.19 &#x000b1; 0.05**</td><td align="center">49.6</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Antitumor effects of Raz on Lewis lung carcinoma in combination with daunorubicin: *Administration every 3 hours. Experimental term was 11 days</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Compounds</td><td align="center">Dosage</td><td align="center">Schedule</td><td align="center">Tumor weight (g)</td><td align="center">Tumor inhibitions</td></tr><tr><td></td><td></td><td colspan="1"><hr></hr></td><td></td><td></td></tr><tr><td></td><td align="center">mg/kg</td><td align="center">1, 5, and 9 administrations</td><td></td><td align="center">%</td></tr></thead><tbody><tr><td align="center">Control</td><td></td><td></td><td align="center">2.34 &#x000b1; 0.05</td><td></td></tr><tr><td align="center">Razoxane (Raz)</td><td align="center">10</td><td align="center">3 times a day*</td><td align="center">1.57 &#x000b1; 0.05</td><td align="center">32.9</td></tr><tr><td align="center">Daunorubicin (Dau)</td><td align="center">2</td><td align="center">1 time a day</td><td align="center">1.10 &#x000b1; 0.04</td><td align="center">53.0</td></tr><tr><td align="center">Raz + Dau</td><td align="center">10 + 2</td><td align="center">3 times/1 time a day</td><td align="center">1.02 &#x000b1; 0.04</td><td align="center">56.4</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Antitumor effects of Raz on Lewis lung carcinoma in combination with bleomycin: * Administrate every 3 hours in one day. ** p &#x0003c; 0.01 (treatment vs vehicle control). Experimental term was 11 days</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Compounds</td><td align="center">Dosage</td><td align="center">Schedule</td><td align="center">Tumor weight</td><td align="center">Tumor Inhibition</td></tr><tr><td></td><td></td><td colspan="1"><hr></hr></td><td></td><td></td></tr><tr><td></td><td align="center">mg/kg</td><td align="center">1, 5, and 9 administration</td><td align="center">(g)</td><td align="center">%</td></tr></thead><tbody><tr><td align="center">Control</td><td align="center">--</td><td align="center">--</td><td align="center">2.46 &#x000b1; 0.06</td><td></td></tr><tr><td align="center">Razoxane (Raz)</td><td align="center">10</td><td align="center">3 times a day*</td><td align="center">1.44 &#x000b1; 0.07</td><td align="center">41.5</td></tr><tr><td align="center">Bleomycin (Ble)</td><td align="center">15</td><td align="center">1 time a day</td><td align="center">1.50 &#x000b1; 0.06</td><td align="center">39.0</td></tr><tr><td align="center">Raz + Ble</td><td align="center">10 + 15</td><td align="center">3 times + 1 time a day</td><td align="center">0.66 &#x000b1; 0.05**</td><td align="center">73.2**</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T7"><label>Table 7</label><caption><p>Antitumor effects of Pro on Lewis lung carcinoma in combination with daunorubicin or bleomycin: *Administration every 3 hours. Experimental term was 11 days</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Compounds</td><td align="center">Dosage</td><td align="center">Schedule</td><td align="center">Body weight</td><td align="center">Tumor weight (g)</td><td align="center">Tumor inhibitions</td></tr><tr><td></td><td></td><td colspan="1"><hr></hr></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">mg/Kg</td><td align="center">1, 5, and 9 administration</td><td align="center">g</td><td></td><td align="center">%</td></tr></thead><tbody><tr><td align="center">Control</td><td align="center">--</td><td align="center">--</td><td align="center">20.6/21.6</td><td align="center">2.62 &#x000b1; 0.08</td><td></td></tr><tr><td align="center">Pro</td><td align="center">20</td><td align="center">3 times a day</td><td align="center">20.6/20.8</td><td align="center">1.45 &#x000b1; 0.07</td><td align="center">44.6</td></tr><tr><td align="center">Dau</td><td align="center">2</td><td align="center">1 time a day</td><td align="center">20.6/20.0</td><td align="center">1.14 &#x000b1; 0.08</td><td align="center">56.5</td></tr><tr><td align="center">Ble</td><td align="center">15</td><td align="center">1 time a day</td><td align="center">20.7/21.2</td><td align="center">1.36 &#x000b1; 0.08</td><td align="center">48.1</td></tr><tr><td align="center">Pro + Dau</td><td align="center">20 + 2</td><td align="center">3 times/1 time a day</td><td align="center">20.6/20.9</td><td align="center">1.07 &#x000b1; 0.05</td><td align="center">59.2</td></tr><tr><td align="center">Pro + Ble</td><td align="center">20 + 15</td><td align="center">3 times/1 time a day</td><td align="center">20.7/19.8</td><td align="center">0.59 &#x000b1; 0.04</td><td align="center">77.5</td></tr></tbody></table></table-wrap></sec><sec><title>Antitumor activity of Pro and Raz on LAX-83</title><p>The experiments showed that LAX-83 was sensitive to <italic>Raz </italic>(40&#x02013;60 mgKg<sup>-1</sup>, ip &#x000d7; 5) and <italic>Pro </italic>(80&#x02013;100 mgKg<sup>-1 </sup>ip &#x000d7; 5) with inhibitory rates of 25&#x02013;32 % and 55&#x02013;60 % respectively (P &#x0003c; 0.01 vs control). <italic>CTX</italic>, as a positive anticancer drug (40 mgKg<sup>-1 </sup>ip &#x000d7; 5), exhibited antitumor activities against the growth of LAX-83 with an inhibitory rate of 84 %. Obvious necrosis in tumor tissues was observed by histological evaluation of <italic>CTX </italic>and <italic>Pro </italic>treatment groups, but <italic>Pro </italic>showed larger vacuoles than <italic>CTX</italic>. Drug inhibition on tumor volumes were calculated and outlined in Table <xref ref-type="table" rid="T8">8</xref>. We have tested the 5 most commonly used anticancer drugs &#x02013; cyclophosphamide (CTX), 5-fluoruoracil (5-Fu), methotrexate (MTX), cisplatin (DDP) and vincristine (VCR) (Table <xref ref-type="table" rid="T9">9</xref>). In the LAX-83 model, CTX has been shown to be the most effective one. The anticancer effect of <italic>Pro </italic>was the same or better than those of MTX, DDP and as well as 5-Fu against LAX-83 tumor growth.</p><table-wrap position="float" id="T8"><label>Table 8</label><caption><p>Antitumor activities of Pro and Raz on human tumor LAX-83 using subrenal capsule assay: Route: ip &#x000d7; 5 daily from the day after surgery. * P &#x0003c; 0.05, ** P &#x0003c; 0.001 (treatment vs vehicle control). Experiment was completed within 7 days. Tumor volume = 1/2 &#x000d7; width<sup>2 </sup>&#x000d7; length (using T-test)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Compounds</td><td align="center">Dosage mg/kg/d</td><td align="center">No mice</td><td align="center">Body weight (g)</td><td align="center">Tumor volume (mm<sup>3</sup>)</td><td align="center">Inhibition%</td></tr></thead><tbody><tr><td align="center">Control</td><td align="center">---</td><td align="center">16</td><td align="center">19.2/21.0</td><td align="center">39.8 &#x000b1; 3.2</td><td align="center">--</td></tr><tr><td align="center">Razoxane</td><td align="center">40</td><td align="center">12</td><td align="center">20.8/21.5</td><td align="center">29.7 &#x000b1; 3.0*</td><td align="center">25</td></tr><tr><td align="center">Razoxane</td><td align="center">60</td><td align="center">12</td><td align="center">19.8/18.8</td><td align="center">27.2 &#x000b1; 2.8*</td><td align="center">32</td></tr><tr><td align="center">Probimane</td><td align="center">80</td><td align="center">12</td><td align="center">20.0/19.6</td><td align="center">18.0 &#x000b1; 2.6**</td><td align="center">55</td></tr><tr><td align="center">Probimane</td><td align="center">100</td><td align="center">12</td><td align="center">20.0/20.0</td><td align="center">15.8 &#x000b1; 2.6**</td><td align="center">60</td></tr><tr><td align="center">Cyclophosphamide</td><td align="center">40</td><td align="center">12</td><td align="center">21.0/20.9</td><td align="center">6.4 &#x000b1; 2.0**</td><td align="center">84</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T9"><label>Table 9</label><caption><p>Antitumor activities of anticancer drugs on human tumor LAX-83 using subrenal capsule assay: Route: ip &#x000d7; 5 daily from the day after surgery. * P &#x0003c; 0.05, ** P &#x0003c; 0.001 (treatment vs vehicle control). Experiment was completed within 7 days. Tumor volume = 1/2 &#x000d7; width<sup>2 </sup>&#x000d7; length (using T-test)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Compounds</td><td align="center">Dosage mg/kg/d</td><td align="center">No mice</td><td align="center">Body weight (g)</td><td align="center">Tumor volume (mm<sup>3</sup>)</td><td align="center">Inhibition%</td></tr></thead><tbody><tr><td align="center">Control</td><td align="center">---</td><td align="center">16</td><td align="center">20.9/22.5</td><td align="center">29.7 &#x000b1; 3.2</td><td align="center">--</td></tr><tr><td align="center">Methotrexate</td><td align="center">1.5</td><td align="center">12</td><td align="center">21.2/21.9</td><td align="center">27.4 &#x000b1; 3.0</td><td align="center">7.7</td></tr><tr><td align="center">Cis-platin</td><td align="center">1.5</td><td align="center">12</td><td align="center">22.8/21.7</td><td align="center">16.6 &#x000b1; 2.6**</td><td align="center">44.1</td></tr><tr><td align="center">5-fluoruoracil</td><td align="center">37.5</td><td align="center">12</td><td align="center">21.7/21.4</td><td align="center">12.8 &#x000b1; 2.6**</td><td align="center">57.5</td></tr><tr><td align="center">Cyclophosphamide</td><td align="center">30.0</td><td align="center">12</td><td align="center">21.0/20.9</td><td align="center">5.8 &#x000b1; 2.3**</td><td align="center">80.5</td></tr><tr><td align="center">Vincristine</td><td align="center">0.3</td><td align="center">12</td><td align="center">20.8/20.8</td><td align="center">7.6 &#x000b1; 2.2**</td><td align="center">74.4</td></tr></tbody></table></table-wrap></sec></sec><sec><title>Discussion</title><p>Explanations of anticancer and antimetastatic mechanisms of <italic>bisdioxopiperazines </italic>are now inconclusive. The present explanation for the anticancer mechanisms of <italic>Raz </italic>has been attributed to antiangiogenesis and topoisomerase II inhibition.[<xref ref-type="bibr" rid="B16">16</xref>] Since the antimetastatic activities of <italic>Raz </italic>and <italic>Pro </italic>were much stronger than those actions against primary tumor growth, this special targeting on metastasis ought to be more useful in clinical cancer treatment. <italic>Raz </italic>and <italic>Pro </italic>show typical characteristics of antiangiogenesis agents, which target small nodule of tumors. Meanwhile, recent reports on drugs targeting <italic>angiogenesis </italic>indicate that most anti-vascular drugs have low or even no effects on most cancers when they are used alone in clinics, but they show synergistic effects in combination with other anticancer drugs. [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>] Our study shows synergistic anticancer actions of <italic>Raz </italic>and <italic>Pro </italic>with <italic>Ble </italic>or <italic>Dau </italic>basing on this theory. Previous work showed that <italic>Pro </italic>and <italic>Raz </italic>could reduce the cardiotoxicity of <italic>anthrocycline</italic>,[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>] so we may reasonably deduce that they can also reduce the cytotoxicity of <italic>anthrocyclines</italic>. The data in our study suggests that the synergistic effects of <italic>Raz </italic>with <italic>anthrocyclines </italic>are present, but not as potent as those with <italic>Ble</italic>.</p><p>Since we have tested the antitumor activity of clinically available anticancer drugs (CTX, 5-Fu, MTX, DDP and VCR) against LAX-83, CTX being the best one, two bisdioxopiperazines studied on this work show overall similar anticancer effective as commonly used drugs. Although the anticancer effects of CTX and VCR are better than those of Pro, for other commonly used drugs, such as DDP, MTX and 5-Fu, the antitumor effects are no better than those of Pro. Since the antitumor effects of MTX and DDP are even less effective than those of <italic>Pro </italic>and <italic>Raz</italic>, we suggest that anticancer effects of <italic>Pro </italic>and <italic>Raz </italic>are within the effective anticancer ranges of commonly available anticancer drugs.</p><p>The other useful property of <italic>Pro </italic>is that it is the most water-soluble among the <italic>bisdioxopiperazines</italic>. Most <italic>bisdioxopiperazines </italic>are less water-soluble and given orally in clinics. Although oral administration is easy for patients, bioavailability varies from patient to patient. For some patients who have a poor absorption of <italic>bisdioxopiperazines </italic>in oral administration, <italic>Pro </italic>can be injected <italic>iv </italic>to maintain stable drug levels. Our previous work showed that <italic>Pro </italic>could strongly accumulate in tumor tissue while <italic>Pro </italic>levels in other tissues decrease rapidly [<xref ref-type="bibr" rid="B19">19</xref>]. Presently, a stereo-isomer of <italic>Raz</italic>, (dexrazoxane, <italic>ICRF-187</italic>), a water-soluble Raz, is being reinvestigated and has aroused the interests of clinical oncologists. Phase III clinical studies are currently underway in the US. More importantly, <italic>ICRF-187 </italic>was licensed in 28 countries in 4 continents. This work shows a noticeable inhibition of <italic>Pro </italic>and <italic>Raz </italic>on lung cancers and suggests possible usage of <italic>Raz </italic>and <italic>Pro </italic>on lung cancer in clinics.</p></sec><sec><title>Conclusions</title><p>The advantages of <italic>bisdioxopiperazines </italic>in clinical treatment of lung cancers are as follows: (i) <italic>Pro </italic>and <italic>Raz </italic>can inhibit the growth of lung cancers, with and without the help of other anticancer drugs, like <italic>Dau </italic>and <italic>Ble</italic>; (ii) like <italic>Raz</italic>, <italic>Pro </italic>strongly inhibits spontaneous pulmonary metastasis of <italic>LLC</italic>; (iii) since <italic>Pro </italic>can inhibit <italic>CaM </italic>[<xref ref-type="bibr" rid="B11">11</xref>], a calcium activated protein that's associated with <italic>MDR </italic>and metastatic phenotypes, synergistic anticancer effects of <italic>Pro </italic>and <italic>Raz </italic>can be expected in combination with other anti-cancer drugs, like <italic>Dau </italic>or <italic>Ble</italic>. Now, new concepts of the relationship between tumor metastasis and <italic>MDR </italic>in cancers have been stated,[<xref ref-type="bibr" rid="B20">20</xref>] whereas <italic>bisdioxopiperazines </italic>can inhibit both tumor metastasis and <italic>MDR</italic>. As a counterpart of <italic>Raz</italic>, <italic>Pro </italic>might be of interest and have chemotherapeutic potential in clinics.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Drugs and animals</title><p>Cyclophosphomide (<italic>CTX</italic>), daunorubicin (<italic>Dau</italic>) and bleomycin (<italic>Ble</italic>), 5-fluororacil (5-Fu), vincristine (VCR), cisplatin (DDP), methotrexate (MTX) were purchased from Shanghai Pharmaceutical Company. Pro and Raz were prepared by Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. C57BL/6J and Kun-Min strain mice were purchased from Shanghai Center of Laboratory Animal Breeding, Chinese Academy of Sciences. Nude mice (Swiss-DF), taken from Roswell Park Memorial Institute, USA, were bred in Shanghai Institute of Materia Medica, Chinese Academy of Sciences under a specific pathogen free condition. Human pulmonary adenocarcinoma xenograft (<italic>LAX-83</italic>)[<xref ref-type="bibr" rid="B21">21</xref>] and Lewis lung carcinoma (<italic>LLC</italic>) were serially transplanted in this laboratory. All animal experiments were conducted in compliance with the Guidelines for the Care and Use of Research Animals, NIH, established by Washington University's Animal Studies Committee. Bouin's solution consists of water saturated with picric acid: formaldehyde: glacial acetic acid (75: 20: 5, v/v/v).</p></sec><sec><title>Lethal dosage determination in mice</title><p>Mice of Kun-Min strain (equal amount of male and female) were <italic>ip </italic>injected with Pro and Raz daily for 10 successive days. The deaths of mice were counted after 1 month. Lethal dosage of agents was calculated by <italic>Random Probity tests</italic>.</p></sec><sec><title>Antitumor and antimetastatic studies of LLC</title><p>C57BL/6J mice were implanted <italic>sc </italic>with <italic>LLC </italic>(2 &#x000d7; 10<sup>6 </sup>cells) from donor mice. The mice were injected intraperitoneally with drugs daily or every two days for 7 injections. On day 11 or day 20, mice were sacrificed, and locally growing tumors were separated from skin and muscles and weighed, and lungs of host mice were placed into a Bouin's solution for 24 h, and then the lung samples were submerged into a solution of 95 % alcohol for 24 h. Finally, the numbers of extruding metastatic foci in lungs were counted.</p></sec><sec><title>Antitumor actions of different schedules and in combinations with different drugs</title><p>C57BL/6J mice were implanted <italic>sc </italic>with <italic>LLC </italic>(2 &#x000d7; 10<sup>6 </sup>cells) from donor mice. Mice were injected intraperitoneally with drugs on day 1, 5, 9. Single injection or 3 injections every 3 hours were used. Tumors were separated and weighed on day 11.</p></sec><sec><title>Antitumor activity study of human tumors</title><p>Nude mice were inoculated with LAX-83 under the renal capsule (SRC method).[<xref ref-type="bibr" rid="B22">22</xref>] Nude mice were injected intraperitoneally with drugs daily during next five days after inoculation of <italic>LAX-83</italic>. Then nude mice were sacrificed, and their kidneys were taken out for measurement of tumor sizes using a stereomicroscope a week after transplantation. Tumor volume was calculated as 1/2(ab<sup>2</sup>) where a and b are their major and minor axes of the lump. Kidneys with tumors were paraffin-embedded, sliced and hematoxylin dyed. The tumor tissues were then observed from a light microscope.</p></sec><sec><title>Statistical analysis</title><p><italic>Student's t-test </italic>was used to assess the differences between control and drug treatment groups of above methods.</p></sec></sec><sec><title>List of abbreviation used are</title><p>Pro, probimane; Raz, razoxane; CaM, calmodulin; LPO, lipoperoxidation; Dau, daunorubicin; Ble, bleomycin; LLC, Lewis lung carcinoma, LAX-83; a lung adenocarcinoma xenograft; ADR, adriamycin;</p></sec><sec><title>Author's contribution</title><p>The experimental design was made by Bin Xu and Da-Yong Lu.</p><p>Experiments were performed by Da-Yong Lu (anticancer activity tests)</p><p>The manuscript was written by Da-Yong Lu, and Jian Ding.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Structural formulas of razoxane and probimane</p></caption><graphic xlink:href="1471-2210-4-32-1"/></fig></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by Science and Technology Foundation of China.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>EH</given-names></name><name><surname>Witiak</surname><given-names>DT</given-names></name><name><surname>Hellmann</surname><given-names>K</given-names></name><name><surname>Waradek</surname><given-names>VS</given-names></name></person-group><article-title>Properties of ICRF-159 and related Bis(dioxopiperazine) compounds</article-title><source>Advances in Pharmacology and Chemotherapy</source><year>1982</year><volume>19</volume><fpage>249</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">6819768</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellmann</surname><given-names>K</given-names></name><name><surname>Rhomberg</surname><given-names>W</given-names></name></person-group><article-title>Radiotherapeutic enhancement by razoxane</article-title><source>Cancer Treat Rev</source><year>1991</year><volume>18</volume><fpage>225</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">1842574</pub-id><pub-id pub-id-type="doi">10.1016/0305-7372(91)90014-Q</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sargent</surname><given-names>JM</given-names></name><name><surname>Williamson</surname><given-names>CJ</given-names></name><name><surname>Yardley</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>CG</given-names></name><name><surname>Hellmann</surname><given-names>K</given-names></name></person-group><article-title>Dexrazoxane significantly impares the induction of doxorubicin resistance the human leukemia line, K562</article-title><source>Brit J Cancer</source><year>2001</year><volume>84</volume><fpage>959</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">11286477</pub-id><pub-id pub-id-type="doi">10.1054/bjoc.2001.1697</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Hille</surname><given-names>B</given-names></name><name><surname>Etievant</surname><given-names>C</given-names></name><name><surname>Barret</surname><given-names>JM</given-names></name><name><surname>Kruczynski</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>BT</given-names></name></person-group><article-title>Characterization of the biological and biochemical activities of F 11782 and bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action</article-title><source>Anti-cancer Drugs</source><year>2000</year><volume>11</volume><fpage>829</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">11142691</pub-id><pub-id pub-id-type="doi">10.1097/00001813-200011000-00007</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>RY</given-names></name></person-group><article-title>Probimane</article-title><source>Drugs Fut</source><year>1988</year><volume>13</volume><fpage>418</fpage><lpage>419</lpage></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>MY</given-names></name><name><surname>Liu</surname><given-names>TX</given-names></name><name><surname>Li</surname><given-names>GT</given-names></name><name><surname>Zhang</surname><given-names>TM</given-names></name></person-group><article-title>Effects of bimolane and probimane on the incorporation of [<sup>3</sup>H]TdR, [<sup>3</sup>H]UR and [<sup>3</sup>H]Leu into Ehrlich ascites carcinoma cells <italic>in vitro</italic></article-title><source>Zhongguo Yuo Li Xue Bao</source><year>1988</year><volume>9</volume><fpage>367</fpage><lpage>369</lpage></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>TM</given-names></name><name><surname>Wang</surname><given-names>MY</given-names></name><name><surname>Wang</surname><given-names>QD</given-names></name></person-group><article-title>Antineoplastic action and toxicity of probimane and its effect on immunologic functions in mice</article-title><source>Zhongguo Yao Li Xue Bao</source><year>1987</year><volume>8</volume><fpage>369</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">3502223</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>KZ</given-names></name><name><surname>Huang</surname><given-names>BY</given-names></name><name><surname>Huang</surname><given-names>TH</given-names></name><name><surname>Wu</surname><given-names>YD</given-names></name></person-group><article-title>Short-term results of malignant lymphoma treated with probimane</article-title><source>Chin J Cancer</source><year>1990</year><volume>9</volume><fpage>192</fpage><lpage>193</lpage></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Hua</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>TM</given-names></name></person-group><article-title>Inhibitory effect of dioxopiperazine compounds on malondialdehyde formation induced by doxorubicin in rat liver mitochondria <italic>in vitro</italic></article-title><source>Zhongguo Yao Li Xue Bao</source><year>1993</year><volume>14</volume><fpage>340</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">8249630</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>QX</given-names></name><name><surname>Zhang</surname><given-names>TM</given-names></name></person-group><article-title>Effects of probimane (Pro) and doxorubicin (Dox) in combination on DNA synthesis and cell cycle of tumor cells</article-title><source>Chin Pharmacol Bull</source><year>1997</year><volume>13</volume><fpage>535</fpage><lpage>537</lpage></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>DY</given-names></name><name><surname>Chen</surname><given-names>EH</given-names></name><name><surname>Cao</surname><given-names>JY</given-names></name><name><surname>Zhou</surname><given-names>JJ</given-names></name><name><surname>Shen</surname><given-names>ZM</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Horie</surname><given-names>K</given-names></name></person-group><article-title>Comparison between probimane and razoxane on inhibiting calmodulin activity of rabbit erythrocyte membrane</article-title><source>Chin J Pharmacol Toxicol</source><year>2001</year><volume>15</volume><fpage>76</fpage><lpage>78</lpage></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>DY</given-names></name><name><surname>Chen</surname><given-names>EH</given-names></name><name><surname>Cao</surname><given-names>JY</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name></person-group><article-title>The inhibition of probimane on lipid peroxidation of rabbit and human erythrocytes</article-title><source>J Shanghai Univ (Eng)</source><year>2003</year><volume>7</volume><fpage>301</fpage><lpage>304</lpage></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>DY</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>MJ</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name></person-group><article-title>Serum contents of sialic acids in mice bearing different tumors</article-title><source>Chin Sci Bull (Eng)</source><year>1994</year><volume>39</volume><fpage>1220</fpage><lpage>1223</lpage></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>DY</given-names></name><name><surname>Chi</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>LP</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name></person-group><article-title>Effects of anticancer drugs on the binding of <sup>125</sup>I-fibrinogen to two leukemia cells <italic>in vitro</italic></article-title><source>J Int Med Res</source><year>2004</year><volume>32</volume><fpage>488</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">15458280</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishio</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Koh</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Fukumoto</surname><given-names>N</given-names></name><name><surname>Saijo</surname><given-names>N</given-names></name></person-group><article-title>Drug resistance in lung cancer</article-title><source>Current Opin Oncol</source><year>1999</year><volume>11</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1097/00001622-199903000-00006</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braybrooke</surname><given-names>JP</given-names></name><name><surname>O'Byrne</surname><given-names>KJ</given-names></name><name><surname>Propper</surname><given-names>DJ</given-names></name><name><surname>Blann</surname><given-names>A</given-names></name><name><surname>Saunders</surname><given-names>M</given-names></name><name><surname>Dobbs</surname><given-names>N</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Woodhull</surname><given-names>J</given-names></name><name><surname>Mitchell</surname><given-names>K</given-names></name><name><surname>Crew</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Stephens</surname><given-names>R</given-names></name><name><surname>Ganesan</surname><given-names>T</given-names></name><name><surname>Talbot</surname><given-names>DC</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><article-title>A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>4697</fpage><lpage>4704</lpage><pub-id pub-id-type="pmid">11156222</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taraboletti</surname><given-names>G</given-names></name><name><surname>Margosio</surname><given-names>B</given-names></name></person-group><article-title>Antiangiogenic and antivascular therapy for cancer</article-title><source>Current Opinion in Pharmacology</source><year>2001</year><volume>1</volume><fpage>378</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">11710736</pub-id><pub-id pub-id-type="doi">10.1016/S1471-4892(01)00065-0</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mark</surname><given-names>J</given-names></name></person-group><article-title>A boost for tumor starvation</article-title><source>Science (Washington DC)</source><year>2003</year><volume>301</volume><fpage>452</fpage><lpage>454</lpage></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JM</given-names></name><name><surname>Xu</surname><given-names>ZD</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>HG</given-names></name><name><surname>Wu</surname><given-names>XH</given-names></name><name><surname>Hait</surname><given-names>WN</given-names></name></person-group><article-title>Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells</article-title><source>Molecular Cancer Res</source><year>2003</year><volume>1</volume><fpage>420</fpage><lpage>427</lpage></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>DY</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>RT</given-names></name></person-group><article-title>Distribution of <sup>14</sup>C labeled at dioxopiperazine or methyl morphorline group of probimane by whole body autoradiography</article-title><source>Zhongguo Yuo Li Xue Bao</source><year>1993</year><volume>14</volume><fpage>171</fpage><lpage>173</lpage></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Dai</surname><given-names>ZQ</given-names></name><name><surname>Shu</surname><given-names>YH</given-names></name><name><surname>Zhang</surname><given-names>JL</given-names></name><name><surname>Lin</surname><given-names>ZQ</given-names></name><name><surname>Wu</surname><given-names>SF</given-names></name><name><surname>Liu</surname><given-names>YF</given-names></name><name><surname>Xu</surname><given-names>LZ</given-names></name></person-group><article-title>Establishment of human lung adenocarcinoma model in nude mice and sensitivity of the transplanted tumor to antitumor drugs</article-title><source>Zhongguo Yuo Li Xue Bao</source><year>1987</year><volume>8</volume><fpage>366</fpage><lpage>369</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Ling</surname><given-names>CQ</given-names></name></person-group><article-title>Tumor chemosensitivity test <italic>in vivo </italic>and subrenal capsule assay</article-title><source>Chin J Cancer</source><year>2002</year><volume>21</volume><fpage>920</fpage><lpage>922</lpage></citation></ref></ref-list></back></article>



